1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades Neurodegenerativas: mecanismos patogénicos

Enfermedades Neurodegenerativas: mecanismos patogénicos

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • García-Rincón D, Díaz-Alonso J, Paraíso-Luna J, Ortega Z, Aguareles J, de Salas-Quiroga A, Jou C, de Prada I, Martínez-Cerdeño V, Aronica E, Guzmán M, Pérez-Jiménez MÁ, Galve-Roperh I.

    Contribution of Altered Endocannabinoid System to Overactive mTORC1 Signaling in Focal Cortical Dysplasia.

    FRONTIERS IN PHARMACOLOGY . 9: 1508-1508. Nº de citas: 10

    [doi:10.3389/fphar.2018.01508]

  • Roig-Puiggros S, Vigouroux RJ, Beckman D, Bocai NI, Chiou B, Davimes J, Gomez G, Grassi S, Hoque A, Karikari TK, Kiffer F, Lopez M, Lunghi G, Mazengenya P, Meier S, Olguín-Albuerne M, Oliveira MM, Paraíso-Luna J, Pradhan J, Radiske A, Ramos-Hryb AB, Ribeiro MC, Schellino R, Selles MC, Singh S, Theotokis P, Chédotal A.

    Construction and reconstruction of brain circuits: normal and pathological axon guidance.

    JOURNAL OF NEUROCHEMISTRY . 153(1): 10-32. Nº de citas: 21

    [doi:10.1111/jnc.14900]

  • Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, Tundidor I, Andradas C, García-Taboada E, Wade J, Smith S, Guzmán M, Pérez-Gómez E, Gordon M, Sánchez C.

    Appraising the entourage effect: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer.

    BIOCHEMICAL PHARMACOLOGY . 157: 285-293.

    [doi:10.1016/j.bcp.2018.06.025]

  • Sagredo O, Palazuelos J, Gutierrez-Rodriguez A, Satta V, Galve-Roperh I, Martínez-Orgado J.

    Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders.

    BIOCHEMICAL PHARMACOLOGY . 157: 85-96. Nº de citas: 17

    [doi:10.1016/j.bcp.2018.08.014]

  • Guzmán M.

    Cannabis for the Management of Cancer Symptoms: THC Version 2.0?

    Cannabis And Cannabinoid Research . 3(1): 117-119.

    [doi:10.1089/can.2018.0009]

  • Moreno E, Chiarlone A, Medrano M, Puigdellívol M, Bibic L, Howell LA, Resel E, Puente N, Casarejos MJ, Perucho J, Botta J, Suelves N, Ciruela F, Ginés S, Galve-Roperh I, Casadó V, Grandes P, Lutz B, Monory K, Canela EI, Lluís C, McCormick PJ, Guzmán M.

    Singular Location and Signaling Profile of Adenosine A 2A -Cannabinoid CB 1 Receptor Heteromers in the Dorsal Striatum.

    NEUROPSYCHOPHARMACOLOGY . 43(5): 964-977.

    [doi:10.1038/npp.2017.12]

  • Ruiz-Calvo A, Maroto IB, Bajo-Grañeras R, Chiarlone A, Gaudioso Á, Ferrero JJ, Resel E, Sánchez-Prieto J, Rodríguez-Navarro JA, Marsicano G, Galve-Roperh I, Bellocchio L, Guzmán M.

    Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors.

    CEREBRAL CORTEX . 28(1): 307-322. Nº de citas: 24

    [doi:10.1093/cercor/bhx285]

  • Mateo Y, Johnson KA, Covey DP, Atwood BK, Wang HL, Zhang S, Gildish I, Cachope R, Bellocchio L, Guzmán M, Morales M, Cheer JF, Lovinger DM.

    Endocannabinoid Actions on Cortical Terminals Orchestrate Local Modulation of Dopamine Release in the Nucleus Accumbens.

    Neuron . 96(5): . Nº de citas: 93

    [doi:10.1016/j.neuron.2017.11.012]

  • Díaz-Alonso J, de Salas-Quiroga A, Paraíso-Luna J, García-Rincón D, Garcez PP, Parsons M, Andradas C, Sánchez C, Guillemot F, Guzmán M, Galve-Roperh I.

    Loss of Cannabinoid CB1 Receptors Induces Cortical Migration Malformations and Increases Seizure Susceptibility.

    CEREBRAL CORTEX . 27(11): 5303-5317. Nº de citas: 27

    [doi:10.1093/cercor/bhw309]

  • Bravo-Ferrer I, Cuartero MI, Zarruk JG, Pradillo JM, Hurtado O, Romera VG, Díaz-Alonso J, García-Segura JM, Guzmán M, Lizasoain I, Galve-Roperh I, Moro MA.

    Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke.

    Stroke . 48(1): 204-212. Nº de citas: 49

    [doi:10.1161/STROKEAHA.116.014793]

  • Hernández-Tiedra S, Fabriàs G, Dávila D, Salanueva ÍJ, Casas J, Montes LR, Antón Z, García-Taboada E, Salazar-Roa M, Lorente M, Nylandsted J, Armstrong J, López-Valero I, McKee CS, Serrano-Puebla A, García-López R, González-Martínez J, Abad JL, Hanada K, Boya P, Goñi F, Guzmán M, Lovat P, Jäättelä M, Alonso A, Velasco G.

    Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization

    Autophagy . 12(11): 2213-2229. Nº de citas: 127

    [doi:10.1080/15548627.2016.1213927]

  • Bellocchio L, Ruiz-Calvo A, Chiarlone A, Cabanas M, Resel E, Cazalets JR, Blázquez C, Cho YH, Galve-Roperh I, Guzmán M.

    Sustained Gq-Protein Signaling Disrupts Striatal Circuits via JNK.

    JOURNAL OF NEUROSCIENCE . 36(41): 10611-10624. Nº de citas: 11

    [doi:10.1523/JNEUROSCI.1192-16.2016]

  • Chiarlone A, Börner C, Martín-Gómez L, Jiménez-González A, García-Concejo A, García-Bermejo ML, Lorente M, Blázquez C, García-Taboada E, de Haro A, Martella E, Höllt V, Rodríguez R, Galve-Roperh I, Kraus J, Guzmán M.

    MicroRNA let-7d is a target of cannabinoid CB1 receptor and controls cannabinoid signaling.

    Neuropharmacology . 108: 345-352. Nº de citas: 22

    [doi:10.1016/j.neuropharm.2016.05.007]

  • Andradas C, Blasco-Benito S, Castillo-Lluva S, Dillenburg-Pilla P, Diez-Alarcia R, Juanes-García A, García-Taboada E, Hernando-Llorente R, Soriano J, Hamann S, Wenners A, Alkatout I, Klapper W, Rocken C, Bauer M, Arnold N, Quintanilla M, Megías D, Vicente-Manzanares M, Urigüen L, Gutkind JS, Guzmán M, Pérez-Gómez E, Sánchez C.

    Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer.

    Oncotarget . 7(30): 47565-47575. Nº de citas: 42

    [doi:10.18632/oncotarget.10206]

  • Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñoz E.

    VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.

    SCIENTIFIC REPORTS . 6: 29789-29789. Nº de citas: 65

    [doi:10.1038/srep29789]

  • López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, Ruiz Romero C, García Ribas G, Alonso Arias MA, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutierrez S, García-Bermejo ML, Fernández Ruiz J, Guzmán M, García de Yébenes Prous J.

    A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

    JOURNAL OF NEUROLOGY . 263(7): 1390-1400. Nº de citas: 105

    [doi:10.1007/s00415-016-8145-9]

  • Velasco G, Sánchez C, Guzmán M.

    Anticancer mechanisms of cannabinoids.

    Current Oncology . 23(2): 23-32. Nº de citas: 206

    [doi:10.3747/co.23.3080]

  • de Salas-Quiroga A, Díaz-Alonso J, García-Rincón D, Remmers F, Vega D, Gómez-Cañas M, Lutz B, Guzmán M, Galve-Roperh I.

    Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA . 112(44): 13693-13698. Nº de citas: 116

    [doi:10.1073/pnas.1514962112]